Mark Newman, Author at Endocrine News

Member News

Remembering Endocrine Society Past-President, Delbert A. Fisher, MD

Delbert A. Fisher, past-president of the Endocrine Society and former editor of The Journal of Clinical Endocrinology & Metabolism, passed away March 4, 2026, at the age of 97. Fisher was a pediatric endocrinologist best known for his work in delineating fetal and newborn thyroid physiology, which led to the launch of newborn screening for...

Pharma Fridays

Pharma Friday – May 8, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Viridian Therapeutics Sees Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease On May 5, Viridian Therapeutics, Inc., announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic...

Italian Researchers Win Endocrine Society’s 2026 Endocrine Images Art Competition

Anna Pilatone and Gabriella Milan won the Endocrine Society’s 2026 Endocrine Images Art Competition for their microscopy image of a pre-adipocyte cell (left). Pilatone and Milan are research biologists in the Endocrine and Metabolic Lab at the Department of Medicine, University of Padova, and at the Center for the Study and Integrated Treatment of Obesity,...

Editor's Page

The First All Adrenal Issue

There’s something fun about “firsts” with such a well-established publication like Endocrine News. This month, I’m pleased to say, is another first: an issue devoted to the adrenal glands, those endocrine glands that “get our juices flowing” so to speak. Senior Editor Derek Bagley has rounded up some of the Endocrine Society’s “Adrenal All Stars”...

Advocacy
- Clinical
- Research

Endocrine Society Advocates on behalf of its Members on Variety of Policy Issues

The Endocrine Society maintains a Government and Public Affairs Department that staffs the organization’s advocacy activities. This Spring the Society has worked on a variety of policy issues that affect our members. This includes: We have provided additional details on some of these topics below. If you are interested in learning more, please contact [email protected]...

Pharma Fridays

Pharma Friday – May 1, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 Trial On April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy...

President's Viewpoint

Looking Back on Presidential Term: Highlights Include Support for Research Members, Progress on Obesity and Advocacy Fronts

As my presidential term winds down, I look back with pride and admiration at the sheer amount of exemplary programming that the Society provides for its members each year. I’d like to recount some highlights from the past 12 months as we prepare to change leadership at ENDO 2026, June 13-16, in Chicago, Ill. One...

Pharma Fridays

Pharma Friday – April 24, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...